Awakn Life Sciences Expands World’s First Ketamine Study Beyond Gambling Disorder to Include Additional Behavioral… Jan 5, 2022
Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key… Jan 4, 2022
Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights Dec 15, 2021
Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as Independent… Dec 14, 2021
Awakn CEO Anthony Tennyson Predicts 2022 Will Be A Big Year For Institutional Investment In Psychedelics Dec 9, 2021
CEOs Kelsey Ramsden and Anthony Tennyson Talk Psychedelic Partnerships: “Further, Faster, Together” Nov 16, 2021
